drugset
drugset / Trial / NCT00098826

SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes

NCT00098826 ↗

Phase 1 Completed 40 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of SB-715992 in treating patients who have acute leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop cancer cells from dividing so they stop growing or die

Timeline

Start
2004-12
Primary completion
2008-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject ispinesib Unknown — Intravenous

Indications

acute erythroid leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with minimal differentiation acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, t(16;16)(p13.1;q22) acute myelomonocytic leukemia M4 acute promyelocytic leukemia acute undifferentiated leukemia adult acute lymphoblastic leukemia adult acute monocytic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive myelodysplastic syndrome with excess blasts refractory anemia with excess blasts in transformation